- Home
- HOV vs PRTA Comparison
HOV vs PRTA Comparison
Compare HOV & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- PRTA
- Stock Information
- Founded
- HOV 1959
- PRTA 2012
- Country
- HOV United States
- PRTA Ireland
- Employees
- HOV N/A
- PRTA N/A
- Industry
- HOV Homebuilding
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- PRTA Health Care
- Exchange
- HOV Nasdaq
- PRTA Nasdaq
- Market Cap
- HOV 843.6M
- PRTA 809.8M
- IPO Year
- HOV N/A
- PRTA N/A
- Fundamental
- Price
- HOV $104.96
- PRTA $12.14
- Analyst Decision
- HOV Sell
- PRTA Buy
- Analyst Count
- HOV 2
- PRTA 9
- Target Price
- HOV $155.00
- PRTA $54.57
- AVG Volume (30 Days)
- HOV 69.2K
- PRTA 454.8K
- Earning Date
- HOV 05-21-2025
- PRTA 05-07-2025
- Dividend Yield
- HOV N/A
- PRTA N/A
- EPS Growth
- HOV 18.84
- PRTA N/A
- EPS
- HOV 32.36
- PRTA N/A
- Revenue
- HOV $3,084,345,000.00
- PRTA $135,157,000.00
- Revenue This Year
- HOV N/A
- PRTA N/A
- Revenue Next Year
- HOV $5.54
- PRTA $131.75
- P/E Ratio
- HOV $3.29
- PRTA N/A
- Revenue Growth
- HOV 8.80
- PRTA 47.92
- 52 Week Low
- HOV $95.27
- PRTA $11.42
- 52 Week High
- HOV $240.34
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- HOV 41.36
- PRTA 38.46
- Support Level
- HOV $100.88
- PRTA $11.42
- Resistance Level
- HOV $106.80
- PRTA $13.52
- Average True Range (ATR)
- HOV 4.20
- PRTA 0.75
- MACD
- HOV 0.41
- PRTA -0.12
- Stochastic Oscillator
- HOV 25.21
- PRTA 24.66
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).